David M. Margolis
#135,081
Most Influential Person Now
Researcher
David M. Margolis's AcademicInfluence.com Rankings
David M. Margoliscomputer-science Degrees
Computer Science
#6149
World Rank
#6483
Historical Rank
Machine Learning
#1901
World Rank
#1926
Historical Rank
Artificial Intelligence
#2149
World Rank
#2185
Historical Rank
Database
#3263
World Rank
#3399
Historical Rank
Download Badge
Computer Science
David M. Margolis's Degrees
- PhD Computer Science Stanford University
Similar Degrees You Can Earn
Why Is David M. Margolis Influential?
(Suggest an Edit or Addition)David M. Margolis's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- SARS-CoV-2 Reverse Genetics Reveals a Variable Infection Gradient in the Respiratory Tract (2020) (1073)
- Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy (2012) (1044)
- The Challenge of Finding a Cure for HIV Infection (2009) (879)
- Making a definitive diagnosis: Successful clinical application of whole exome sequencing in a child with intractable inflammatory bowel disease (2011) (695)
- SARS-CoV-2 D614G variant exhibits efficient replication ex vivo and transmission in vivo (2020) (681)
- The receptor binding domain of the viral spike protein is an immunodominant and highly specific target of antibodies in SARS-CoV-2 patients (2020) (664)
- Towards an HIV cure: a global scientific strategy (2012) (520)
- Effect of NASA light-emitting diode irradiation on wound healing. (2001) (474)
- Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study (2013) (470)
- Depletion of latent HIV-1 infection in vivo: a proof-of-concept study (2005) (420)
- International AIDS Society global scientific strategy: towards an HIV cure 2016 (2016) (372)
- Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. (2009) (358)
- An In-Depth Comparison of Latent HIV-1 Reactivation in Multiple Cell Model Systems and Resting CD4+ T Cells from Aviremic Patients (2013) (358)
- The Human Factors YY1 and LSF Repress the Human Immunodeficiency Virus Type 1 Long Terminal Repeat via Recruitment of Histone Deacetylase 1 (2000) (350)
- Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. (2000) (348)
- Long-acting intramuscular cabotegravir and rilpivirine in adults with HIV-1 infection (LATTE-2): 96-week results of a randomised, open-label, phase 2b, non-inferiority trial (2017) (339)
- Inhibition of HIV fusion with multivalent gold nanoparticles. (2008) (337)
- Precise Quantitation of the Latent HIV-1 Reservoir: Implications for Eradication Strategies. (2015) (324)
- The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial (2010) (307)
- Coaxing HIV-1 from resting CD4 T cells: histone deacetylase inhibition allows latent viral expression (2004) (274)
- Eradicating HIV-1 infection: seeking to clear a persistent pathogen (2014) (261)
- The impact of active herpes simplex virus infection on human immunodeficiency virus load. (1997) (250)
- Epigenetic Silencing of HIV-1 by the Histone H3 Lysine 27 Methyltransferase Enhancer of Zeste 2 (2011) (241)
- One-unit versus two-unit cord-blood transplantation for hematologic cancers. (2014) (239)
- BET bromodomain inhibition as a novel strategy for reactivation of HIV‐1 (2012) (237)
- Counterregulation of Chromatin Deacetylation and Histone Deacetylase Occupancy at the Integrated Promoter of Human Immunodeficiency Virus Type 1 (HIV-1) by the HIV-1 Repressor YY1 and HIV-1 Activator Tat (2002) (230)
- HIV-1 expression within resting CD4+ T cells after multiple doses of vorinostat. (2014) (229)
- HIV reservoirs: what, where and how to target them (2015) (220)
- Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort (2010) (218)
- Immediate antiviral therapy appears to restrict resting CD4+ cell HIV-1 infection without accelerating the decay of latent infection (2012) (216)
- c-Myc and Sp1 Contribute to Proviral Latency by Recruiting Histone Deacetylase 1 to the Human Immunodeficiency Virus Type 1 Promoter (2007) (212)
- Long-acting injectable antiretrovirals for HIV treatment and prevention (2013) (209)
- Initial antibodies binding to HIV-1 gp41 in acutely infected subjects are polyreactive and highly mutated (2011) (205)
- Latency reversal and viral clearance to cure HIV-1 (2016) (199)
- A Limited Group of Class I Histone Deacetylases Acts To Repress Human Immunodeficiency Virus Type 1 Expression (2009) (198)
- Evidence of dysregulation of dendritic cells in primary HIV infection. (2010) (185)
- Disulfiram Reactivates Latent HIV-1 in a Bcl-2-Transduced Primary CD4+ T Cell Model without Inducing Global T Cell Activation (2011) (183)
- Valproic acid without intensified antiviral therapy has limited impact on persistent HIV infection of resting CD4+ T cells (2008) (175)
- Generation of HIV Latency in Humanized BLT Mice (2011) (174)
- Long-Acting Cabotegravir and Rilpivirine for Maintenance of HIV-1 Suppression. (2020) (173)
- Polyclonal B Cell Differentiation and Loss of Gastrointestinal Tract Germinal Centers in the Earliest Stages of HIV-1 Infection (2009) (173)
- Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial. (2015) (166)
- Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women. (2021) (163)
- Expression of latent human immunodeficiency type 1 is induced by novel and selective histone deacetylase inhibitors (2009) (162)
- Pulmonary, gonadal, and central nervous system status after bone marrow transplantation for sickle cell disease. (2010) (161)
- Emerging strategies to deplete the HIV reservoir (2014) (161)
- Antiretroviral Intensification and Valproic Acid Lack Sustained Effect on Residual HIV-1 Viremia or Resting CD4+ Cell Infection (2010) (155)
- Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial. (2017) (154)
- Activation of CD8+ T lymphocytes through the T cell receptor turns on CD4 gene expression: implications for HIV pathogenesis. (1998) (151)
- A trial of unrelated donor marrow transplantation for children with severe sickle cell disease. (2016) (149)
- Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. (2020) (145)
- Snapshots: chromatin control of viral infection. (2013) (140)
- Interval dosing with the HDAC inhibitor vorinostat effectively reverses HIV latency (2017) (138)
- Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo (2020) (135)
- Severe hepatitis in three AIDS patients treated with indinavir (1997) (131)
- Spatiotemporal trafficking of HIV in human plasmacytoid dendritic cells defines a persistently IFN-α-producing and partially matured phenotype. (2011) (131)
- Higher macrophage inflammatory protein (MIP)-1α and MIP-1β levels from CD8+ T cells are associated with asymptomatic HIV-1 infection (2000) (131)
- Quantitation of Replication-Competent HIV-1 in Populations of Resting CD4+ T Cells (2014) (128)
- Allogeneic hematopoietic cell transplantation for XIAP deficiency: an international survey reveals poor outcomes. (2013) (126)
- Chronic graft‐versus‐host disease of the liver: Presentation as an acute hepatitis (2000) (125)
- Histone deacetylase inhibitors and HIV latency (2011) (121)
- Abacavir and mycophenolic acid, an inhibitor of inosine monophosphate dehydrogenase, have profound and synergistic anti-HIV activity. (1999) (121)
- Human transcription factor YY1 represses human immunodeficiency virus type 1 transcription and virion production (1994) (120)
- Newborn Screening for Severe Combined Immunodeficiency; The Wisconsin Experience (2008–2011) (2012) (119)
- The Control of HIV After Antiretroviral Medication Pause (CHAMP) Study: Posttreatment Controllers Identified From 14 Clinical Studies (2018) (115)
- Safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in low-risk HIV-uninfected individuals: HPTN 077, a phase 2a randomized controlled trial (2018) (110)
- Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. (2015) (108)
- The replication-competent HIV-1 latent reservoir is primarily established near the time of therapy initiation (2019) (108)
- Atazanavir for the Treatment of Human Immunodeficiency Virus Infection (2004) (108)
- No Effect of Raltegravir Intensification on Viral Replication Markers in the Blood of HIV-1–Infected Patients Receiving Antiretroviral Therapy (2012) (107)
- Reactivation of latent HIV-1 in central memory CD4+ T cells through TLR-1/2 stimulation (2013) (107)
- Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy after sustained virologic suppression. (2006) (104)
- Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial (2021) (103)
- Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells (2020) (102)
- Targeted Cytotoxic Therapy Kills Persisting HIV Infected Cells During ART (2014) (102)
- Ruxolitinib for treatment of refractory hemophagocytic lymphohistiocytosis. (2017) (101)
- Superior survival associated with transplantation of matched unrelated versus one-antigen-mismatched unrelated or highly human leukocyte antigen-disparate haploidentical family donor marrow grafts for the treatment of hematologic malignancies: establishing a treatment algorithm for recipients of alt (2002) (100)
- Genomics in Clinical Practice: Lessons from the Front Lines (2013) (99)
- Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes (1995) (98)
- Degradation of Polycomb Repressive Complex 2 with an EED-targeted Bivalent Chemical Degrader (2019) (97)
- Mechanisms of HIV Latency: an Emerging Picture of Complexity (2010) (95)
- Upper gastrointestinal disease in chronic renal failure. A prospective evaluation. (1978) (94)
- Transactivation of the HIV-1 LTR by HSV-1 immediate-early genes. (1992) (92)
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 48-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study (2020) (92)
- T-cell depletion plus salvage immunotherapy with donor leukocyte infusions as a strategy to treat chronic-phase chronic myelogenous leukemia patients undergoing HLA-identical sibling marrow transplantation. (1999) (92)
- Clonal Sequences Recovered from Plasma from Patients with Residual HIV-1 Viremia and on Intensified Antiretroviral Therapy Are Identical to Replicating Viral RNAs Recovered from Circulating Resting CD4+ T Cells (2011) (91)
- Unrelated donor bone marrow transplantation to treat severe aplastic anaemia in children and young adults (1996) (86)
- Curing HIV: Pharmacologic approaches to target HIV-1 latency. (2011) (84)
- USF/c-Myc enhances, while Yin-Yang 1 suppresses, the promoter activity of CXCR4, a coreceptor for HIV-1 entry. (1999) (83)
- The addition of mycophenolate mofetil to antiretroviral therapy including abacavir is associated with depletion of intracellular deoxyguanosine triphosphate and a decrease in plasma HIV-1 RNA. (2002) (83)
- IL-2 receptor γ-chain molecule is critical for intestinal T-cell reconstitution in humanized mice (2012) (83)
- Prospects for Treatment of Latent HIV (2013) (82)
- Experiences with long acting injectable ART: A qualitative study among PLHIV participating in a Phase II study of cabotegravir + rilpivirine (LATTE-2) in the United States and Spain (2018) (82)
- Expanded cytotoxic T-cell lymphocytes target the latent HIV reservoir. (2015) (82)
- Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo (2018) (81)
- A timely arrival for genomic medicine (2011) (81)
- Suppression of Human Immunodeficiency Virus Type 1 (HIV-1) Viremia with Reverse Transcriptase and Integrase Inhibitors, CD4+ T-Cell Recovery, and Viral Rebound upon Interruption of Therapy in a New Model for HIV Treatment in the Humanized Rag2−/−γc−/− Mouse (2009) (81)
- Repression of Human Immunodeficiency Virus Type 1 through the Novel Cooperation of Human Factors YY1 and LSF (1998) (81)
- Hexamethylbisacetamide and disruption of human immunodeficiency virus type 1 latency in CD4(+) T cells. (2008) (80)
- Curing HIV: Seeking to Target and Clear Persistent Infection (2020) (79)
- Cross-Sectional Detection of Acute HIV Infection: Timing of Transmission, Inflammation and Antiretroviral Therapy (2011) (78)
- Latent HIV-1 Infection of Resting CD4+ T Cells in the Humanized Rag2−/− γc −/− Mouse (2011) (77)
- HIV latency is reversed by ACSS2-driven histone crotonylation (2018) (77)
- Safety and immunogenicity of a heptavalent pneumococcal conjugate vaccine in infants with human immunodeficiency virus type 1 infection. (2003) (77)
- Rifaximin has a marginal impact on microbial translocation, T-cell activation and inflammation in HIV-positive immune non-responders to antiretroviral therapy - ACTG A5286. (2015) (73)
- Analysis of risk factors for the development of GVHD after T cell-depleted allogeneic BMT: effect of HLA disparity, ABO incompatibility, and method of T-cell depletion. (2001) (71)
- Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial (2016) (70)
- Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. (2007) (69)
- Long-acting antiviral agents for HIV treatment (2015) (69)
- Dose proportional inhibition of HIV-1 replication by mycophenolic acid and synergistic inhibition in combination with abacavir, didanosine, and tenofovir. (2002) (68)
- Cognitive and psychosocial functioning of pediatric hematopoietic stem cell transplant patients: A prospective longitudinal study (2002) (67)
- Targeted Derepression of the Human Immunodeficiency Virus Type 1 Long Terminal Repeat by Pyrrole-Imidazole Polyamides (2002) (64)
- Infection Rates among Acute Leukemia Patients Receiving Alternative Donor Hematopoietic Cell Transplantation. (2016) (64)
- Higher macrophage inflammatory protein (MIP)-1alpha and MIP-1beta levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. (2000) (63)
- Induction and enhancement of immune responses to herpes simplex virus type 2 in humans by use of a recombinant glycoprotein D vaccine. (1993) (61)
- Selective HDAC Inhibition for the Disruption of Latent HIV-1 Infection (2014) (60)
- The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function (2016) (60)
- HIV antibodies for treatment of HIV infection (2017) (60)
- Polyamides reveal a role for repression in latency within resting T cells of HIV-infected donors. (2004) (60)
- Regimen simplification to atazanavir-ritonavir alone as maintenance antiretroviral therapy: final 48-week clinical and virologic outcomes. (2009) (59)
- Benzotriazoles Reactivate Latent HIV-1 through Inactivation of STAT5 SUMOylation (2017) (59)
- HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model (2013) (58)
- Effect of T cell subset dose on outcome of T cell-depleted bone marrow transplantation (1997) (58)
- Gold nanoparticles to improve HIV drug delivery. (2015) (58)
- Combined approaches for HIV cure (2013) (57)
- Association of Crohn's disease, thiopurines, and primary epstein-barr virus infection with hemophagocytic lymphohistiocytosis. (2011) (57)
- HIV-1 proviral landscapes distinguish posttreatment controllers from noncontrollers (2018) (57)
- Antiretroviral Therapy Initiated During Acute HIV Infection Fails to Prevent Persistent T-Cell Activation (2013) (56)
- Peripheral Vγ9Vδ2 T Cells Are a Novel Reservoir of Latent HIV Infection (2015) (56)
- HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal. (2017) (55)
- Tail-phase safety, tolerability, and pharmacokinetics of long-acting injectable cabotegravir in HIV-uninfected adults: a secondary analysis of the HPTN 077 trial. (2020) (55)
- H3K27 Demethylation at the Proviral Promoter Sensitizes Latent HIV to the Effects of Vorinostat in Ex Vivo Cultures of Resting CD4+ T Cells (2015) (53)
- Radiation-free, alternative-donor HCT for Fanconi anemia patients: results from a prospective multi-institutional study. (2017) (53)
- The regulation of HIV-1 gene expression: the emerging role of chromatin. (2002) (52)
- Single-Cell Analysis of Quiescent HIV Infection Reveals Host Transcriptional Profiles that Regulate Proviral Latency. (2018) (51)
- In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection (2016) (49)
- Alternative-donor hematopoietic stem-cell transplantation for severe aplastic anemia. (2000) (49)
- CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption (2020) (49)
- Long-Acting Injectable Cabotegravir + Rilpivirine for HIV Maintenance Therapy: Week 48 Pooled Analysis of Phase 3 ATLAS and FLAIR Trials (2020) (49)
- Envelope-specific antibodies and antibody-derived molecules for treating and curing HIV infection (2016) (48)
- Hexamethylbisacetamide Remodels the Human Immunodeficiency Virus Type 1 (HIV-1) Promoter and Induces Tat-Independent HIV-1 Expression but Blunts Cell Activation (2006) (47)
- Proviral Latency, Persistent Human Immunodeficiency Virus Infection, and the Development of Latency Reversing Agents. (2017) (47)
- Abacavir in combination with the inosine monophosphate dehydrogenase (IMPDH)-inhibitor mycophenolic acid is active against multidrug-resistant HIV-1. (1999) (47)
- Therapy for Latent HIV-1 Infection: The Role of Histone Deacetylase Inhibitors (2014) (46)
- Cyclosporin A provides no sustained immunologic benefit to persons with chronic HIV-1 infection starting suppressive antiretroviral therapy: results of a randomized, controlled trial of the AIDS Clinical Trials Group A5138. (2006) (46)
- Monitoring and modulation of Epstein–Barr virus loads in pediatric transplant patients (2003) (46)
- HIV Latency-Reversing Agents Have Diverse Effects on Natural Killer Cell Function (2016) (46)
- Framing expectations in early HIV cure research. (2014) (45)
- Broadly-specific cytotoxic T cells targeting multiple HIV antigens are expanded from HIV+ patients: implications for immunotherapy. (2015) (45)
- Long-acting cabotegravir plus rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label, phase 3 FLAIR study. (2021) (44)
- Chlamydia pneumoniaeInhibits Apoptosis in Human Peripheral Blood Mononuclear Cells Through Induction of IL-10 (2000) (43)
- Interrupting antiretroviral treatment in HIV cure research: scientific and ethical considerations (2017) (43)
- Disposition and metabolism of cabotegravir: a comparison of biotransformation and excretion between different species and routes of administration in humans (2016) (42)
- Splenic rupture in a parental donor undergoing peripheral blood progenitor cell mobilization. (2004) (42)
- HLA-B*57 Elite Suppressor and Chronic Progressor HIV-1 Isolates Replicate Vigorously and Cause CD4+ T Cell Depletion in Humanized BLT Mice (2014) (42)
- Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis (2021) (42)
- Effect of myeloablative bone marrow transplantation on growth in children with sickle cell anaemia: results of the multicenter study of haematopoietic cell transplantation for sickle cell anaemia (2007) (41)
- Immunogenicity of AGS-004 Dendritic Cell Therapy in Patients Treated During Acute HIV Infection. (2017) (41)
- Determination of human immunodeficiency virus RNA in plasma and cellular viral DNA genotypic zidovudine resistance and viral load during zidovudine-didanosine combination therapy (1995) (41)
- Pharmaceutical approaches to eradication of persistent HIV infection (2009) (40)
- Interleukin-7 induces HIV type 1 outgrowth from peripheral resting CD4+ T cells. (2004) (40)
- Allogeneic Hematopoietic Cell Transplantation Using Treosulfan-Based Conditioning for Treatment of Marrow Failure Disorders. (2017) (40)
- Satisfaction and acceptability of cabotegravir long-acting injectable suspension for prevention of HIV: Patient perspectives from the ECLAIR trial (2018) (40)
- Acute HIV-1 infection in the Southeastern United States: a cohort study. (2013) (38)
- Ischemic bowel disease following bilateral nephrectomy or renal transplant. (1977) (36)
- Multi-omics analyses reveal that HIV-1 alters CD4 T cell immunometabolism to fuel virus replication (2021) (36)
- Eradication therapies for HIV Infection: time to begin again. (2011) (36)
- Effect of the weaver (wv) mutation on cerebellar neuron differentiation. I. Qualitative observations of neuron behavior in culture. (1985) (36)
- New Frontiers in Measuring and Characterizing the HIV Reservoir (2019) (35)
- Endoscopic Diagnosis of Pediatric Acute Gastrointestinal Graft-Versus-Host Disease (2012) (35)
- Chromatin Regulation and the Histone Code in HIV Latency (2017) (34)
- Detection of nonnucleoside reverse-transcriptase inhibitor-resistant HIV-1 after discontinuation of virologically suppressive antiretroviral therapy. (2008) (34)
- Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in convalescent individuals (2021) (33)
- Cytomegalovirus-specific cytolytic T-cell lines and clones generated against adenovirus-pp65-infected dendritic cells. (2001) (33)
- Single cell analysis of quiescent HIV infection reveals host transcriptional profiles that regulate proviral latency (2018) (33)
- HIV-Specific, Ex Vivo Expanded T Cell Therapy: Feasibility, Safety, and Efficacy in ART-Suppressed HIV-Infected Individuals. (2018) (33)
- Efficacy of NNRTI-based antiretroviral therapy initiated during acute HIV infection (2011) (33)
- Expanding the Menu of HIV Prevention Options: A Qualitative Study of Experiences with Long-Acting Injectable Cabotegravir as PrEP in the Context of a Phase II Trial in the United States (2018) (32)
- Improvement in Insulin Sensitivity and Dyslipidemia in Protease Inhibitor-Treated Adult Male Patients After Switch to Atazanavir/Ritonavir (2008) (32)
- Words matter: Discussing research towards an HIV cure in research and clinical contexts. (2014) (32)
- A Pilot Study of the Use of Mycophenolate Mofetil as a Component of Therapy for Multidrug‐Resistant HIV‐1 Infection (2001) (31)
- How Might We Cure HIV? (2014) (29)
- A Cure for HIV Infection: “Not in My Lifetime” or “Just Around the Corner”? (2016) (29)
- Evaluation of Chiron HIV-1/HIV-2 recombinant immunoblot assay (1996) (28)
- Simplification to Abacavir/Lamivudine + Atazanavir Maintains Viral Suppression and Improves Bone and Renal Biomarkers in ASSURE, a Randomized, Open Label, Non-Inferiority Trial (2014) (28)
- HSV-1 activation of HIV-1 transcription is augmented by a cellular protein that binds near the initiator element. (1993) (28)
- Transcriptomic Analysis Implicates the p53 Signaling Pathway in the Establishment of HIV-1 Latency in Central Memory CD4 T Cells in an In Vitro Model (2016) (27)
- Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF (1997) (27)
- Vorinostat Renders the Replication-Competent Latent Reservoir of Human Immunodeficiency Virus (HIV) Vulnerable to Clearance by CD8 T Cells (2017) (27)
- Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes (1994) (27)
- Sequence Evaluation and Comparative Analysis of Novel Assays for Intact Proviral HIV-1 DNA (2020) (26)
- HLA-B*57:01 allele prevalence in HIV-infected North American subjects and the impact of allele testing on the incidence of abacavir-associated hypersensitivity reaction in HLA-B*57:01-negative subjects (2017) (26)
- Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077 (2020) (26)
- Mixed effects of suberoylanilide hydroxamic acid (SAHA) on the host transcriptome and proteome and their implications for HIV reactivation from latency. (2015) (26)
- Efficacy of alemtuzumab treatment for refractory T-cell large granular lymphocytic leukemia. (2004) (25)
- Effect of the weaver (wv) mutation on cerebellar neuron differentiation. II. Quantitation of neuron behavior in culture. (1985) (25)
- Characterizing the Switching Thresholds of Magnetophoretic Transistors (2015) (25)
- Predictors of Residual Viraemia in Patients on Long-Term Suppressive Antiretroviral Therapy (2012) (25)
- Factors affecting neutrophil and platelet reconstitution following T cell-depleted bone marrow transplantation: differential effects of growth factor type and role of CD34+ cell dose (2001) (24)
- HIV Persistence on Antiretroviral Therapy and Barriers to a Cure. (2018) (24)
- Ten Years of Screening and Testing for Acute HIV Infection in North Carolina (2016) (24)
- The use of β-D-2,6-diaminopurine dioxolane with or without mycophenolate mofetil in drug-resistant HIV infection (2007) (24)
- Adoptive immunotherapy for leukemia: donor lymphocytes transduced with the herpes simplex thymidine kinase gene for remission induction. HGTRI 0103. (1998) (24)
- Inflammatory biomarker changes and their correlation with Framingham cardiovascular risk and lipid changes in antiretroviral-naive HIV-infected patients treated for 144 weeks with abacavir/lamivudine/atazanavir with or without ritonavir in ARIES. (2012) (24)
- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study. (2021) (23)
- Cabotegravir is Not Associated with Weight Gain in HIV-uninfected Individuals in HPTN 077. (2020) (23)
- Mitogen-Activated Protein Kinases Regulate LSF Occupancy at the Human Immunodeficiency Virus Type 1 Promoter (2005) (23)
- γδ T cells: an immunotherapeutic approach for HIV cure strategies. (2018) (23)
- Fatal Ergotism Induced by an HIV Protease Inhibitor (2002) (23)
- Quantification of the Latent HIV-1 Reservoir Using Ultra Deep Sequencing and Primer ID in a Viral Outgrowth Assay (2017) (23)
- A pilot study of the use of mycophenolate mofetil as a component of therapy for multidrug-resistant HIV-1 infection. (2001) (23)
- Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection (2020) (23)
- The RBD Of The Spike Protein Of SARS-Group Coronaviruses Is A Highly Specific Target Of SARS-CoV-2 Antibodies But Not Other Pathogenic Human and Animal Coronavirus Antibodies (2020) (23)
- Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170) (2012) (22)
- Lessons for Patient Education Around Long-Acting Injectable PrEP: Findings from a Mixed-Method Study of Phase II Trial Participants (2018) (22)
- Intertriginous eruption associated with chemotherapy in pediatric patients. (2007) (21)
- Epigenomic characterization of latent HIV infection identifies latency regulating transcription factors (2020) (20)
- Focal nodular hyperplasia in pediatric allogeneic hematopoietic cell transplant: case series (2010) (20)
- Unrelated donor bone marrow transplantation for myelodysplastic syndrome in children. (2011) (20)
- Effect of race on outcomes after allogeneic hematopoietic cell transplantation for severe aplastic anemia (2011) (20)
- SMAC Mimetic Plus Triple-Combination Bispecific HIVxCD3 Retargeting Molecules in SHIV.C.CH505-Infected, Antiretroviral Therapy-Suppressed Rhesus Macaques (2020) (19)
- Long-acting injectable therapy: an emerging paradigm for the treatment of HIV infection. (2019) (19)
- In vitro T‐cell receptor Vβ repertoire analysis may identify which T‐cell Vβ families mediate graft‐versus‐leukaemia and graft‐versus‐host responses after human leucocyte antigen‐matched sibling stem cell transplantation (2001) (19)
- Neuronal differentiation in cultures of weaver (wv) mutant mouse cerebellum. (1981) (19)
- Patient-reported tolerability and acceptability of cabotegravir + rilpivirine long-acting injections for the treatment of HIV-1 infection: 96-week results from the randomized LATTE-2 study (2019) (19)
- HIV eradication symposium: will the brain be left behind? (2015) (19)
- Longitudinal dynamics of intact HIV proviral DNA and outgrowth virus frequencies in a cohort of ART-treated individuals. (2020) (19)
- In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals (2019) (18)
- The HIV-1 latent reservoir is largely sensitive to circulating T cells (2019) (18)
- Improved Killing of HIV-infected Cells Using Three Neutralizing and Non-neutralizing Antibodies. (2020) (17)
- Long-acting cabotegravir + rilpivirine for HIV-1 treatment: ATLAS week 96 results. (2021) (17)
- Ex vivo modeling of the effects of mycophenolic acid on HIV infection: considerations for antiviral therapy. (2005) (17)
- Dose-responsive gene expression in suberoylanilide hydroxamic acid-treated resting CD4+ T cells (2015) (17)
- Malignant infantile osteopetrosis & primary pulmonary hypertension: A new combination? (2004) (16)
- Discovery of a large-scale, cell-state-responsive allosteric switch in the 7SK RNA using DANCE-MaP. (2022) (16)
- The role of reactive oxygen intermediates in experimental coccidioidomycois in mice (2011) (16)
- HIV-Specific T Cell Responses Are Highly Stable on Antiretroviral Therapy (2019) (15)
- Treatment with recombinant growth hormone is associated with modest improvement in CD4 lymphocyte reconstitution in HIV-infected persons on antiretroviral therapy: results of ACTG A5174. (2010) (15)
- HIV-Specific T Cells Generated from Naive T Cells Suppress HIV In Vitro and Recognize Wide Epitope Breadths. (2018) (15)
- Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials (2020) (15)
- Determinants of the efficacy of HIV latency-reversing agents and implications for drug and treatment design. (2018) (15)
- Impact of biological sex on immune activation and frequency of the latent HIV reservoir during suppressive antiretroviral therapy. (2020) (14)
- The SMAC Mimetic AZD5582 is a Potent HIV Latency Reversing Agent (2018) (14)
- Suppression of EBV release from irradiated B lymphoblastoid cell-lines: superior activity of ganciclovir compared with acyclovir. (2003) (14)
- Hydroxyethyl starch as a substitute for dextran 40 for thawing peripheral blood progenitor cell products. (2015) (14)
- Therapy for persistent HIV. (2010) (14)
- Alternative donor bone marrow transplant for children with Philadelphia chromosome ALL (2006) (13)
- Evaluation of EED Inhibitors as a Class of PRC2-Targeted Small Molecules for HIV Latency Reversal (2020) (13)
- Selective targeting of the repressive transcription factors YY1 and cMyc to disrupt quiescent human immunodeficiency viruses. (2012) (13)
- Longitudinal Dynamics of Intact HIV Proviral DNA and Outgrowth Virus Frequencies in a Cohort of Individuals Receiving Antiretroviral Therapy (2021) (13)
- A cutaneous lesion in a patient with AIDS: an unusual presentation of infection due to Mycobacterium avium complex. (1993) (13)
- Persistence by proliferation? (2014) (13)
- CD4+ T-cell decline after the interruption of antiretroviral therapy in ACTG A5170 is predicted by differential expression of genes in the ras signaling pathway. (2008) (12)
- Rhabdomyolysis associated with high-dose cytarabine. (1987) (12)
- How Unavoidable Are Analytical Treatment Interruptions in HIV Cure-Related Studies? (2019) (12)
- Attacking latent HIV provirus: from mechanism to therapeutic strategies (2006) (12)
- Control of thymidine incorporation in mucosal explants from patients with chronic ulcerative colitis (1980) (11)
- Voriconazole-induced blistering in the setting of graft versus host disease: A report of 2 patients. (2008) (11)
- Attacking HIV provirus: therapeutic strategies to disrupt persistent infection. (2006) (11)
- A placebo-controlled pilot study of intensification of antiretroviral therapy with mycophenolate mofetil (2006) (11)
- Control of thymidine incorporation in mucosal explants from patients with chronic ulcerative colitis. (1980) (11)
- Measuring the Inducible, Replication-Competent HIV Reservoir Using an Ultra-Sensitive p24 Readout, the Digital ELISA Viral Outgrowth Assay (2020) (10)
- Translational challenges in targeting latent HIV infection and the CNS reservoir problem (2015) (10)
- Gemella morbillorum mediastinitis and osteomyelitis following transesophageal endoscopic ultrasound-guided fine-needle aspiration of a posterior mediastinal lymph node. (2007) (10)
- Confronting proviral HIV infection (2007) (10)
- Yin and Yang of mesenchymal stem cells and aplastic anemia (2017) (10)
- Improved Measures of Quality of Life, Lipid Profile, and Lipoatrophy After Treatment Interruption in HIV-Infected Patients With Immune Preservation: Results of ACTG 5170 (2008) (10)
- Inhibition of HIV replication by A77 1726, the active metabolite of leflunomide, in combination with pyrimidine nucleoside reverse transcriptase inhibitors. (2001) (9)
- Detection of human immunodeficiency virus RNAs in living cells using Spinach RNA aptamers. (2017) (9)
- Unsuspected brucellosis diagnosed in a child as a result of an outbreak of laboratory-acquired brucellosis. (1993) (9)
- Risk Factors for Subsequent Central Nervous System Tumors in Pediatric Allogeneic Hematopoietic Cell Transplant: A Study from the Center for International Blood and Marrow Transplant Research (CIBMTR). (2017) (9)
- Author Correction: Robust and persistent reactivation of SIV and HIV by N-803 and depletion of CD8+ cells (2020) (9)
- LB2. Safety and Efficacy of Combination SARS-CoV-2 Monoclonal Neutralizing Antibodies (mAb) BRII-196 and BRII-198 in Non-Hospitalized COVID-19 Patients (2021) (9)
- Towards an HIV Cure: a View of a Developing Field. (2017) (9)
- Week 96 extension results of a Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment (2021) (9)
- How to cure AIDS: feeling the elephant. (2015) (8)
- Septicemic plague in a community hospital in California. (2008) (8)
- Reversible parkinsonism in a child after bone marrow transplantation and lipid-based amphotericin B therapy. (1998) (8)
- Patient-Reported Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine Administered Every 4 or 8 Weeks (ATLAS-2M) (2021) (8)
- “I feel empowered”: women’s perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain (2020) (8)
- Contribution of prostaglandin E2 to the interleukin-12 defect in HIV-infected patients. (1996) (8)
- Stable Latent HIV Infection and Low-Level Viremia Despite Treatment with the Broadly Neutralizing Antibody VRC07-523LS and the Latency Reversal Agent Vorinostat. (2021) (8)
- Efficacy, Safety, and Durability of Long-Acting Cabotegravir and Rilpivirine in Adults With Human Immunodeficiency Virus Type 1 Infection: 5-Year Results From the LATTE-2 Study (2021) (7)
- Successful autologous cord blood transplantation in a child with acquired severe aplastic anemia (2013) (7)
- Highlights from the Seventh International Workshop on HIV Persistence during Therapy, 8–11 December 2015, Miami, Florida, USA (2016) (7)
- Eliminating persistent HIV infection: getting to the end of the rainbow. (2007) (7)
- Quantitative relationship between platelet count and plasma virion HIV RNA. (1996) (7)
- Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis (2021) (7)
- Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo (2022) (7)
- Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals (2021) (6)
- Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir (2020) (6)
- Frequency of Post Treatment Control Varies by ART Restart and Viral Load Criteria. (2021) (6)
- Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761) (2014) (6)
- Multiparametric magnetic resonance imaging to characterize cabotegravir long‐acting formulation depot kinetics in healthy adult volunteers (2021) (6)
- Change‐point models to estimate the limit of detection (2013) (6)
- Generation of cytotoxic T-cell lines using overlapping pentadecapeptides derived from conserved regions of the adenovirus hexon protein. (2010) (6)
- Interferon inactivator(s) in patients with AIDS and AIDS-unrelated Kaposi's sarcoma. (1987) (5)
- Expanding community engagement in HIV clinical trials: a pilot study using crowdsourcing. (2020) (5)
- Single‐center experience suggests donor lymphocyte infusion may promote long‐term survival in children with high‐risk acute lymphoblastic leukemia (2019) (5)
- Treatment for lipoatrophy: facing the real costs. (2007) (5)
- Long-acting cabotegravir and rilpivirine for maintenance of HIV-1 suppression: pOLAR month 12 results. (2021) (5)
- Crotonylation sensitizes IAPi-induced disruption of latent HIV by enhancing p100 cleavage into p52 (2021) (5)
- Phase II trial using haploidentical hematopoietic cell transplantation (HCT) followed by donor natural killer (NK) cell infusion and sirolimus maintenance for patients with high-risk solid tumors. (2020) (5)
- Hormonal Contraception Use and Cabotegravir Pharmacokinetics in HIV-Uninfected Women Enrolled in HPTN 077. (2020) (5)
- 8th IAS Conference on HIV Pathogenesis, Treatment & Prevention 19–22 July 2015, Vancouver, Canada (2015) (5)
- Depletion of Latent HIV Infection In Vivo : Moving Towards Eradication of HIV Infection (2005) (5)
- Fixed-dose combination emtricitabine/tenofovir/efavirenz initiated during acute HIV infection; 96-week efficacy and durability (2016) (4)
- Recent molecular and cellular advances in pediatric bone marrow transplantation. (2006) (4)
- Outcomes of Convalescent Plasma with Defined High versus Lower Neutralizing Antibody Titers against SARS-CoV-2 among Hospitalized Patients: CoronaVirus Inactivating Plasma (CoVIP) Study (2022) (4)
- Outcomes of convalescent plasma with defined high- versus lower-neutralizing antibody titers against SARS-CoV-2 among hospitalized patients: CoronaVirus Inactivating Plasma (CoVIP), double-blind phase 2 study. (2022) (4)
- Cellular Gene Modulation of HIV-Infected CD4 T Cells in Response to Serial Treatment with the Histone Deacetylase Inhibitor Vorinostat (2020) (4)
- Four Weeks of Treatment With Rifaximin Fails to Significantly Alter Microbial Diversity in Rectal Samples of HIV-Infected Immune Non-Responders (ACTG A5286) Which May be Attributed to Rectal Swab Use (2019) (4)
- Association of HIV neutralizing antibody with lower viral load after treatment interruption in a prospective trial (A5170). (2012) (4)
- Countering HIV — Three's the Charm? (2018) (4)
- The use of pentoxifylline alone in HIV-infected patients. (1994) (4)
- CD8 Lymphocyte Depletion Enhances the Latency Reversal Activity of the SMAC Mimetic AZD5582 in ART-Suppressed Simian Immunodeficiency Virus-Infected Rhesus Macaques (2021) (4)
- Compact Quadruple Therapy with the Lamivudine/Zidovudine Combination Tablet Plus Abacavir and Efavirenz, Followed by the Lamivudine/Zidovudine/Abacavir Triple Nucleoside Tablet Plus Efavirenz in Treatment-Naïve HIV-Infected Adults (2003) (4)
- Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa (2016) (4)
- Erratum: Administration of vorinostat disrupts HIV-1 latency in patients on antiretroviral therapy (2012) (3)
- 520. Pharmacokinetic and Safety Phase 1 Study and Microneutralization Assay Results with BRII-196/BRII-198, a Novel Antibody Cocktail Active Against a Wide Range of SARS-CoV-2 Variants (2021) (3)
- Determination of the Volume of HPC, Apheresis Products Based on Weight in Grams (2014) (3)
- Differential effects of HIV latency-reversing agents on T cell phenotype and function: implications for HIV cure (2015) (3)
- Elimination of SHIV Infected Cells by Combinations of Bispecific HIVxCD3 DART® Molecules (2021) (3)
- Chemotherapy-Only Preparative Regimen for Alternative Donor Hematopoietic Cell Transplantation for Patients with Fanconi Anemia (FA): Results of a Multi-Institutional Study (2015) (3)
- Hematopoietic stem cell transplantation for severe aplastic anemia. (1998) (3)
- Erratum: Prospects for Treatment of Latent HIV (Clinical Pharmacology and Therapeutics (2013) 93 (46-56) DOI: 10.1038/clpt.2012.202) (2013) (3)
- Efficacy, pharmacokinetics and neurocognitive performance of dual, NRTI-sparing antiretroviral therapy in acute HIV-infection. (2020) (3)
- Chemotherapy-Only Preparative Regimen for T-Cell Depleted Hematopoietic Stem Cell Transplantation of Patients with Fanconi Anemia From Alternative Donors (2012) (3)
- Corrigendum: The differential short- and long-term effects of HIV-1 latency-reversing agents on T cell function (2016) (3)
- 2497. Women’s Perspectives on and Experiences with Long-acting Injectable Anti-retroviral Therapy in the United States and Spain: the Potential Role of Gender in Patient Preferences (2019) (3)
- Mouse weaver mutation affects granule cell neurite growth in vitro. (1983) (3)
- Severe muscle spasms: an unusual manifestation of hypothyroidism. (1981) (2)
- Effects of Rifaximin on the Rectal Microbiome in HIV-Infected Immune Nonresponders on Antiretroviral Therapy (ACTG A5286) (2019) (2)
- Erratum for Markmann et al., “Sex Disparities and Neutralizing-Antibody Durability to SARS-CoV-2 Infection in Convalescent Individuals” (2021) (2)
- Reply to Cooper et al. (2008) (2)
- Highlights of the 9th edition of the Conference on HIV Persistence During Therapy, 10–13 December 2019, Miami, USA (2020) (2)
- Early therapy‐related myeloid sarcoma and deletion of 9q22.32 to q31.1 (2014) (2)
- PE 20 LB Assay to measure the latent reservoir of replication-competent HIV-1 in suppressed patients based on ultra deep sequencing (2015) (2)
- CTLA-4 and PD-1 dual blockade induces SIV reactivation without control of rebound after antiretroviral therapy interruption (2020) (2)
- Defining Stable Reference Genes in HIV Latency Reversal Experiments (2021) (2)
- Highlights from the 8th International Workshop on HIV Persistence during Therapy, 12–15 December 2017, Miami, FL, USA (2018) (2)
- Immunological correlates of the HIV-1 replication-competent reservoir size. (2021) (2)
- Altered Response Pattern following AZD5582 Treatment of SIV-Infected, ART-Suppressed Rhesus Macaque Infants (2022) (2)
- Medicinal chemistry: Forcing an enemy into the open. (2012) (2)
- drug-resistant Vibrio cholerae O1 in San Pedro Sula, Honduras (1997) (2)
- A modified viral outgrowth assay incorporating ultra-sensitive P24 measurements (2017) (2)
- Title The role of reactive oxygen intermediates in experimental coccidioidomycois in mice Permalink (2011) (2)
- Partially CD3+-depleted unrelated and haploidentical donor PSCT has favorable GVHD and survival rates in pediatric hematologic malignancy. (2019) (2)
- The Path to Cure: Using Haploidentical (haplo) Donors and High-Dose Post-Transplant Cyclophosphamide (PTCy) for Treatment-Naïve and Refractory Severe Aplastic Anemia (SAA) (2019) (2)
- P04-45. Characterization of the plasma cell repertoire in acute HIV-1 infection (AHI) (2009) (2)
- International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK (2016) (2)
- 638. Safety, Efficacy, and Durability of Long-Acting CAB and RPV as Maintenance Therapy for HIV-1 Infection: LATTE-2 Week 256 Results (2020) (2)
- LB-8. Summary of COVID-Related Impact on Cabotegravir and Rilpivirine Long-Acting (CAB+RPV LA) Dosing Across the Six Ongoing Global Phase IIb and IIIb Clinical Trials (2020) (2)
- Improved Cell Viability, Viable Cell Recovery and Faster Engraftment of Products Thawed Using a Premixed Solution of Human Serum Albumin and Dextran 40 Compared to Sequential Addition During the Thawing Procedure (2010) (1)
- HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model (2013) (1)
- Contribution of prostaglandin (PG) E2 to the IL-12 defect in HIV-infected (HIV+) patients (1996) (1)
- Abstracts of the 8th HIV Persistence during Therapy Workshop (2017) (1)
- Preclinical development of a bispecific HIV x CD3 DART molecule that redirects T cells to kill HIV envelope (env)-expressing cells (2017) (1)
- Favorable Chronic Graft-Versus-Host-Disease (GVHD), Event-Free (EFS), and Overall Survival (OS) Rates Following Partially CD3-Depleted Alternative Donor Peripheral Stem Cell Transplantation (PSCT) for Pediatric Hematologic Malignancies (2016) (1)
- Bispecific antibody-derived molecules to target persistent HIV infection (2022) (1)
- HIV-Specific T CELLS Expanded from HIV+ and HIV-Naive Donors Target a Range of Viral Epitopes: Implications for a Cure Strategy after Allogeneic HSCT (2017) (1)
- HPTN 069/ACTG A5305: phase II study of maraviroc-containing regimens for HIV PrEP in US women; Postive impact of a randomized controlled trial of the Uthando Lwethu ("Our Love") intervention on rates of couples HIV testing in rural South Africa (2016) (1)
- 116. Antiviral Activity and Safety of Long-acting Cabotegravir (CAB LA) Plus Long-acting Rilpivirine (RPV LA), Administered Every 2 Months (Q2M), in Hiv-positive Subjects: Results from the POLAR Study (2020) (1)
- A-102 Antibody binding to HIV-1 infected cells as mechanism for treatment of HIV infection (2018) (1)
- 1037. Qualitative Findings from a Hybrid III Implementation-Effectiveness Study to Explore Perspectives of Health-care Staff on Early Implementation of Cabotegravir and Rilpivirine Long Acting (CAB+RPV LA) Injectable HIV treatment in the US (CUSTOMIZE) (2020) (1)
- High Rate of Adverse Events Associated with Rifabutin Therapy for Pulmonary MAC: Experience of a Large Referral Center (2005) (1)
- Aplastic Anemia & MDS International Foundation (AA&MDSIF): Bone Marrow Failure Disease Scientific Symposium 2018. (2019) (1)
- Long-acting cabotegravir and rilpivirine for HIV-1 suppression: switch to 2-monthly dosing after 5 years of daily oral therapy (2021) (1)
- A histone deacetylase network regulates epigenetic reprogramming and viral silencing in HIV infected cells (2022) (1)
- CD8+ lymphocytes do not impact SIV reservoir establishment under ART (2023) (1)
- Early production of donor-derived CD4+ CD25+ regulatory T cells in patients given hematopoietic stem cell transplants (2004) (1)
- Microglia-Specific Promoter Activities of HEXB Gene (2022) (1)
- Chemotherapy-Only Preparative Regimen for Alternative Donor Hematopoietic Stem Cell Transplantation for Patients with Fanconi Anemia (2012) (1)
- Feasibility of implementing long-acting injectable anti-retroviral therapy to treat HIV: a survey of health providers from the 13 countries participating in the ATLAS-2M trial. (2020) (1)
- Large-scale allosteric switch in the 7SK RNA regulates transcription in response to growth and stress (2021) (1)
- Pancreatitis associated with brain tumor therapy. (1994) (1)
- The latency reversal activity of the SMAC mimetic AZD5582 in ART-suppressed SIV-infected rhesus macaques is potentiated by CD8a cell depletion (2019) (1)
- Hematopoietic Cell Transplantation for Childhood Acute Myeloid Leukemia (2009) (1)
- Reactivation of latent HIV-1 in central memory CD4+T cells through TLR-1/2 stimulation (2013) (1)
- Allogeneic Transplantation for Acute Myeloid Leukemia in Children (2007) (1)
- Measuring the haystack's needles. (2020) (1)
- Treatments for persistent HIV infection: the road ahead (2010) (1)
- Sequential transplantation and implications for clinical management: OLT followed by HCT and consequent RT in a pediatric patient (2019) (1)
- 1021. HIV-1 RNA Blips and Low-Level Replication During Phase III/IIIb Cabotegravir + Rilpivirine Long-Acting Studies Are Similar to Oral 3-Drug Therapy and Not Associated with Week 48 Virologic Outcome (2020) (1)
- Evaluation of a COVID-19 convalescent plasma program at a U.S. academic medical center (2022) (1)
- 1035. Patient-Reported Outcomes on Long-Acting Cabotegravir + Rilpivirine as Maintenance Therapy: FLAIR 96-Week Results (2020) (1)
- Title Dendritic cell immunotherapy for HIV-1 infection using autologous HIV-1 RNA : A randomized , double-blind , placebo-controlled clinical trial Permalink (0)
- Correction to: HIV Persistence on Antiretroviral Therapy and Barriers to a Cure. (2018) (0)
- CD8 depletion plus signaling of the non-canonical NF-kB pathway reverses latency in SIV-infected, ART-suppressed rhesus macaques (2019) (0)
- Epigenomic characterisation of a primary cell model of HIV latency (2019) (0)
- PHARMACOLOGICAL REACTIVATION OF VIRUS AS A CURE STRATEGY (2014) (0)
- Bone Marrow Failure (2019) (0)
- Prevention, suppression or eradication of viral infection: Paradigms for dealing with the challenges of Human Immunodeficiency Virus (2002) (0)
- Cross-reactivity of Epstein Barr virus-specific cytotoxic T lymphocytes with a HLA-C locus allele (2005) (0)
- Targeted screens identify new chromatin regulators of HIV latency (2017) (0)
- Persistent HIV infection in newborns: how soon is soon enough? (2014) (0)
- A trip down memory lane with Retrovirology (2019) (0)
- Correction: The Effect of Raltegravir Intensification on Low-level Residual Viremia in HIV-Infected Patients on Antiretroviral Therapy: A Randomized Controlled Trial (2011) (0)
- Attacking latent HIV: towards eradication of HIV infection (2006) (0)
- PP 4.24 – 00176 Impact of cannabis use on immune cell populations and the viral reservoir in HIV-infected people on suppressive antiretroviral therapy (2022) (0)
- B-104 HIV cure research: a status report (2016) (0)
- Sex disparities and neutralizing antibody durability to SARS-CoV-2 infection in individuals (2021) (0)
- October 2012 Prospects for Treatment of Latent HIV (2012) (0)
- PP 2.9 – 00125 Impact of latency reversal agents on estrogen receptor alpha gene and protein expression (2022) (0)
- The SMAC mimetic AZD5582 reverses HIV latency as a single agent in resting primary CD4+ T cells (2019) (0)
- PP 1.4 – 00037 Histone decrotonylation uniquely regulates HIV-1 transcription and can be modulated to control HIV-1 latency (2022) (0)
- HIV post-treatment controllers have distinct immunological and virological features. (2023) (0)
- S021-04 OA. A large-scale analysis of immunoglobulin sequences derived from plasmablasts/plasma cells in acute HIV-1 infection subjects (2009) (0)
- Commentary on increased risk of prostate cancer among HIV-infected men (2005) (0)
- The utility of the Connectivity Map (CMAP) for HIV cure strategies (2015) (0)
- Blood Dendritic Cell Subsets in Early HIV Infection (2008) (0)
- Sting agonist as a kick and kill agent to target the HIV reservoir (2019) (0)
- Latency Reversal and Clearance of Persistent HIV Infection. (2022) (0)
- PP 3.11 – 00171 The chromatin insulator CTCF inhibits HIV gene expression (2022) (0)
- In Vitro Techniques for Studies of HIV-1 Promoter Activity. (1999) (0)
- Human Papillomavirus ( HPV ) Genotype 84 Infection of the Male Genitalia : Further Evidence for HPV Tissue Tropism ? (2008) (0)
- Hexamethylbisacetamide and Disruption of Human Immunodeficiency Virus Type 1 Latency in CD4 (cid:1) T Cells (2008) (0)
- Correction for Garrido et al., “Interleukin-15-Stimulated Natural Killer Cells Clear HIV-1-Infected Cells following Latency Reversal Ex Vivo” (2020) (0)
- Erratum: Treatment with Recombinant Growth Hormone Is Associated with Modest Improvement in CD4 Lymphocyte Reconstitution in HIV-Infected Persons on Antiretroviral Therapy: Results of ACTG A5174 (AIDS Research and Human Retroviruses (2010) 26 (425-432)) (2010) (0)
- A truncated HIV Tat demonstrates potent and specific latency reversal activity (2023) (0)
- Specificity of bivalent chemical degraders targeted to the BET proteins (2019) (0)
- Improved killing of HIV-infected cells by a combination of three antibodies: implications for clearing persistent infection (2019) (0)
- HIV eradication symposium: will the brain be left behind? (2015) (0)
- Systemic HIV and SIV latency reversal via non-canonical NF-κB signalling in vivo (2020) (0)
- Impact of cannabis use on immune cell populations and the viral reservoir in people with HIV on suppressive antiretroviral therapy (2022) (0)
- Transcriptomic Signatures of Human Immunodeficiency Virus Post-Treatment Control (2022) (0)
- Issues for Cure Clinical Trials - Measured Steps Towards Eradication (2014) (0)
- Crotonate sensitizes IAPi in the disruption of latent HIV by modulating the ncNF‐κB signaling pathway at the step of p100 cleavage into p52 (2022) (0)
- Erratum: Repression of human immunodeficiency virus type 1 through the novel cooperation of human factors YY1 and LSF (Journal of Virology 71:12 (9382)) (1998) (0)
- HIV-Specific T Cells Generated from HIV-Naive Adult and Cord Blood Donors Target a Range of Viral Epitopes' Implications for a Cure Strategy after Allogeneic Stem Cell Transplant (2017) (0)
- Therapy for Persistent HI (2010) (0)
- The impact of vorinostat and AGS-004, a dendritic cell-based immunotherapy, on persistent HIV-1 Infection (2019) (0)
- Assessing the impact of AGS-004, a dendritic cell-based immunotherapy, and vorinostat on persistent HIV-1 Infection (2020) (0)
- Traitement VIH : Une étude internationale dans le prestigieux New England Journal of Medicine (2020) (0)
- Translational challenges in targeting latent HIV infection and the CNS reservoir problem (2014) (0)
- Adenovirus-based vaccines against HIV : A look at how the immune system could be trained to combat HIV (0)
- PP 4.14 – 00173 Antiretroviral therapy repairs CD4 T cell dysregulation in people living with HIV (2022) (0)
- Another Step Toward Eliminating HIV Infection (2013) (0)
- Microglia-specific promoter activities of human HexB gene (2021) (0)
- Crotonylation Sensitizes IAPI-Induced Disruption of Latent HIV by Modulating ncNF-κB Signaling at the Step of p100 Cleavage Into p52 (2021) (0)
- 1029. Long-Term Patient Adherence and Management of Treatment Interruptions With Long-Acting Injectable Cabotegravir + Rilpivirine for Maintenance Therapy in Phase IIb/III Studies (2020) (0)
- 552. Evaluation of Relationships Between UGT1A1 Genotypes and Cabotegravir Long-Acting Injection Pharmacokinetics Among HIV-Infected Subjects in the LATTE-2 Study (2018) (0)
- Combinatorial latency reversal activity of inhibitor of apoptosis antagonists with mechanistically distinct classes of HIV latency reversal agents (2019) (0)
- Track B Clinical Science (2012) (0)
- Use of locus of control and self-efficacy to predict outcome in alcohol treatment (1992) (0)
- Liver Transplant Associated Systemic Graft-Versus-Host Disease Following Complete Donor Hematopoietic Chimerism (2021) (0)
- CD4 T cell memory restoration upon antiretroviral initiation in people living with HIV. (2020) (0)
- 115. Immune-modulation therapy in a CRIM negative Pompe disease patient blocks antibody formation towards Myozyme, reverses cardiomyopathy, and prolongs survival (2009) (0)
- Analysis Of The Incidence And Characteristics Of Venoocclusive Disease (VOD) Of The Liver In Pediatric Hematopoietic Progenitor Cell Transplant (HPCT) Patients With Heparin Alone Vs. Heparin And Ursodiol Prophylaxis At The Medical College Of Wisconsin (2010) (0)
- Long Term Outcomes of Unrelated Donor Bone Marrow Transplantation in Children with Severe Aplastic Anemia: An Update of the Milwaukee Experience. (2006) (0)
- Factors predictive of poor recovery of viable CD34+ cells in thawed/washed HPC, apheresis products (2015) (0)
- 927: Sedated Lymphocyte and Stem Cell Collection With Dexmedetomidine (2020) (0)
- Use of a Potassium Channel Blocker to Inhibit Effector-Memory T Cells Isolated from Recipients of Allogeneic BMSCT. (2008) (0)
- Dexmedetomidine for sedation during hematopoietic stem cell harvest apheresis and leukapheresis in the PICU: Guideline development. (2022) (0)
- Generation of Multi-Specific CTL Lines Using Overlapping Pentadecapeptide Pools of Aspergillus f16 and Adenovirus Hexon Antigens Presented on Epstein Barr Virus-Transformed B Cells as Antigen Presenting Cells. (2006) (0)
- PP 3.10 – 00168 Vpr synergizes with vorinostat to prevent HIV-1 latency establishment (2022) (0)
- Ex Vivo Expanded Multi-Specific Cytotoxic T Lymphocytes Derived from HIV+ Patients and HIV Negative Donors Using GMP Compliant Methodologies Recognize Multiple HIV Antigens and Suppress HIV Replication (2013) (0)
- Approaches to eradication of latent HIV infection (2013) (0)
- Approaches to eradication of latent HIV infection (2013) (0)
- 85 - HIV specific T cells generated from HIV naive adult and cord blood donors target a range of novel viral epitopes—implications for a cure strategy after allogeneic HSCT and CBT (2017) (0)
- Quantifying Virus Escape from T Cells in the Latent HIV Reservoir (2019) (0)
- Do T cells from HIV-infected individuals have normal metabolic function? (2017) (0)
- The use of hydroxyethyl starch (HES) as a substitute for dextran 40 in the thaw and washing of HPC, apheresis products (2015) (0)
- In vitro demonstration of a potential role for STING agonist in HIV cure (2019) (0)
- PP 1.33 – 00167 Integrated single-cell multi-omic profiling of HIV latency reversal (2022) (0)
- Protein crotonylation sensitizes SMACm disruption of latent HIV by modulating the ncNF-κB signaling pathway at the step of p100 cleavage into p52 (2019) (0)
- Ex Vivo Expanded HIV-Specific T Cells From HIV+ Patients and Virus-Naïve Donors are Functionally Active: Implications for a Cure Strategy Post HSCT (2016) (0)
- Proposal for the generation of HIV-specific T cells from art patients (2013) (0)
- In vivo analysis of the effect of panobinostat on cell-associated HIV RNA and DNA levels and latent HIV infection (2016) (0)
- Highlights from the Tenth International Workshop on HIV Persistence during Therapy, December 13-16, 2022, Miami, Florida-USA (2023) (0)
- PP 1.24 – 00132 BET PROTACS Reveal BRD4 Disruption of the 7SK/P-TEFb Equilibrium is Critical for Effective Reactivation of Latent HIV in CD4+ T-cells (2022) (0)
- Effects of different treatment regimens on T cell function in acute HIV infection. (2016) (0)
- Analysis of the Incidence and Characteristics of Venoocclusive Disease (VOD) of the Liver in Pediatric Hematopoietic Progenitor Cell Transplant (HPCT) Patients with Heparin Alone Vs. Heparin and Ursodiol Prophylaxis at the Medical College of Wisconsin. (2009) (0)
- Evaluation of IAP/SMAC mimetics as latency reversal agents in primary cells and cytokine induction in in vivo models predictive of cytokine release (2019) (0)
- HIV-specific T cells generated from HIV-naive adult and cord blood donors target a range of novel viral epitopes: implications for a cure strategy after allogeneic HSCT and CBT (2017) (0)
- Conserved-region MVA vaccines can shift HIV T cell immunodominance in PWH on ART - the M&M Study (2022) (0)
- 24 HIV-specific, ex vivo expanded T cell therapy (HXTC) for HIV clearance: feasibility, safety and efficacy (2017) (0)
- "Tailoring" Hematopoietic Progenitor Cell Collection: Impact of a Data-Driven Prediction Algorithm for Blood Volume Processing in Large Volume Leukapheresis (2016) (0)
- Integrated single-cell multiomic analysis of HIV latency reversal reveals novel regulators of viral reactivation (2022) (0)
- The Role of Race on Survival after Alternative Donor Hematopoietic Progenitor Cell Transplant for Pediatric Acute Leukemia: Provocative Single Center Data. (2004) (0)
- Autologous Stem Cell Collection for the Treatment of Malignant Diseases in Pediatric Patients: The Use of the Power Hickman (2013) (0)
- Validation of conditions required to control the rate of freezing of cellular therapy products cryopreserved by overnight storage at -80 c (2014) (0)
- a Coreceptor for HIV-1 Entry CXCR4, Suppresses, the Promoter Activity of USF/c-Myc Enhances, While Yin-Yang 1 (1999) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With David M. Margolis?
David M. Margolis is affiliated with the following schools:
